CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid ... and secured approvals for 16 new drug applications (NDAs) covering 9 indications.

The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell ...

Upon FDA clearance of the IND application, Tiziana plans to commence a 20-patient clinical trial of two doses of Tiziana’s novel and patented therapeutic candidate, intranasal foralumab ...

Gireesh Babu, New Delhi Thursday, February 27, 2025, 08:00 Hrs [IST] ...

CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types. Building on promising data from CS5001 monotherapy in later-line aggressive and ...

based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical program and to activate multiple clinical trial ...

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...